Podcast Episodes
Back to Search
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
Season 3 Episode 70
With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their …
1 year, 10 months ago
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
Season 3 Episode 69
CMS’s controversial decision to restrict access to Alzheimer’s mAb treatments, including Aduhelm, approved under FDA’s accelerated pathway was a uniq…
1 year, 11 months ago
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process
Season 3 Episode 68
Few CEOs have built a $20 billion biotech in under 15 years, as John Oyler has with BeiGene, managing to stay in that market cap band even through th…
1 year, 11 months ago
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
Season 3 Episode 67
There is good news in this year’s Association for Accessible Medicines report on savings from biosimilars, including a 30% increase over the last yea…
2 years ago
Popular Episode - Bob Nelsen on AI, China and the IRA
Season 3
This is a previously recorded episode of The BioCentury Show from February 22, 2024. Subscribe to this channel to listen to each new episode. Visit T…
2 years ago
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine
Season 3 Episode 66
As Jane Grogan anticipates the unmet needs in patients five years from now, she’s harnessing a wave of interest in targeting B cells as a key driver …
2 years ago
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact
Season 3 Episode 65
As Astellas prepares to launch four products in parallel, Chief Commercial Officer Claus Zieler is balancing the complexity of this multi-faceted ent…
2 years, 1 month ago
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing
Season 3 Episode 64
Ignorance about the path from scientific discovery to approved drugs, high out-of-pocket costs, and a byzantine healthcare system that obscures net p…
2 years, 1 month ago
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up
Season 3 Episode 63
Pediatric cancer drug development is difficult: it requires high levels of safety, involves parents as well as the patients, and has small population…
2 years, 2 months ago
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat
Season 3 Episode 62
The U.S. is experiencing events that are either the first stages of a widespread avian influenza outbreak or a fire drill that will show how well the…
2 years, 2 months ago